Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 165,400 shares, a growth of 61.8% from the August 15th total of 102,200 shares. Based on an average trading volume of 709,900 shares, the days-to-cover ratio is currently 0.2 days.
Hedge Funds Weigh In On Catalyst Biosciences
Large investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. purchased a new position in Catalyst Biosciences during the second quarter worth about $36,000. Bank of New York Mellon Corp lifted its position in Catalyst Biosciences by 187.9% during the first quarter. Bank of New York Mellon Corp now owns 216,807 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 141,498 shares during the period. Acadian Asset Management LLC purchased a new position in Catalyst Biosciences during the first quarter worth about $52,000. Finally, Renaissance Technologies LLC lifted its position in Catalyst Biosciences by 38.2% during the third quarter. Renaissance Technologies LLC now owns 1,101,270 shares of the biopharmaceutical company’s stock worth $555,000 after buying an additional 304,284 shares during the period. 5.98% of the stock is currently owned by hedge funds and other institutional investors.
Catalyst Biosciences Trading Down 1.4 %
Shares of NASDAQ:CBIO traded down $0.01 on Friday, hitting $0.55. The company had a trading volume of 116,789 shares, compared to its average volume of 621,491. Catalyst Biosciences has a 52-week low of $0.19 and a 52-week high of $1.98. The business has a 50 day moving average of $0.44 and a 200 day moving average of $0.31. The company has a market cap of $20.89 million, a PE ratio of -0.37 and a beta of 1.02.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.
- Five stocks we like better than Catalyst Biosciences
- Stock Splits, Do They Really Impact Investors?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 9/11 – 9/15
- Compound Interest and Why It Matters When Investing
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.